Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Pegloticase
Therapeutic Area : Rheumatology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pegloticase is a Enzyme drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Gout.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
January 29, 2024
Lead Product(s) : Pegloticase
Therapeutic Area : Rheumatology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegloticase,Methotrexate
Therapeutic Area : Rheumatology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The co-administration of KRYSTEXXA (pegloticase) with an immunomodulator like methotrexate has increasingly been employed in patients with uncontrolled gout to help reduce the development of antidrug antibodies, which can affect treatment efficacy with b...
Product Name : Krystexxa
Product Type : Enzyme
Upfront Cash : Inapplicable
November 08, 2022
Lead Product(s) : Pegloticase,Methotrexate
Therapeutic Area : Rheumatology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegloticase,Methotrexate
Therapeutic Area : Rheumatology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The MIRROR randomized controlled trial outcomes provided a clear view of improvements in patient response and reductions in infusion reactions for KRYSTEXXA plus low-dose (15 mg/week) methotrexate compared to KRYSTEXXA plus placebo.
Product Name : Krystexxa
Product Type : Enzyme
Upfront Cash : Inapplicable
June 01, 2022
Lead Product(s) : Pegloticase,Methotrexate
Therapeutic Area : Rheumatology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegloticase,Methotrexate
Therapeutic Area : Rheumatology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : KRYSTEXXA® (pegloticase injection) is a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy.
Product Name : Krystexxa
Product Type : Enzyme
Upfront Cash : Inapplicable
May 24, 2022
Lead Product(s) : Pegloticase,Methotrexate
Therapeutic Area : Rheumatology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegloticase,Methotrexate
Therapeutic Area : Rheumatology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Application based on recent MIRROR randomized controlled trial results, which showed 71% of patients randomized to receive KRYSTEXXA (pegloticase), a PEGylated uric acid specific enzyme plus methotrexate achieved a complete response.
Product Name : Krystexxa
Product Type : Enzyme
Upfront Cash : Inapplicable
March 07, 2022
Lead Product(s) : Pegloticase,Methotrexate
Therapeutic Area : Rheumatology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegloticase,Methotrexate
Therapeutic Area : Rheumatology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : sBLA Submission based on recent results from the MIRROR randomized clinical trial, which showed a 71% response rate for patients randomized to receive KRYSTEXXA (Pegloticase) PEGylated uric acid specific enzyme, plus methotrexate for people living with u...
Product Name : Krystexxa
Product Type : Enzyme
Upfront Cash : Inapplicable
January 10, 2022
Lead Product(s) : Pegloticase,Methotrexate
Therapeutic Area : Rheumatology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegloticase,Methotrexate
Therapeutic Area : Rheumatology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The results from the completed PROTECT trial (NCT04087720) demonstrated that Krystexxa (Pegloticase & Methotrexate) provide a substantial and sustained decrease in serum uric acid (sUA) for patients with uncontrolled gout who had received a kidney transp...
Product Name : Krystexxa
Product Type : Enzyme
Upfront Cash : Inapplicable
November 04, 2021
Lead Product(s) : Pegloticase,Methotrexate
Therapeutic Area : Rheumatology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegloticase,Methotrexate
Therapeutic Area : Rheumatology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The findings indicated that the use of KRYSTEXXA with an immunomodulator may improve persistence to therapy. Approx 90% of the evaluated population met the sUA treatment target and those who received immunomodulation after starting on KRYSTEXXA were less...
Product Name : Krystexxa
Product Type : Enzyme
Upfront Cash : Inapplicable
November 01, 2021
Lead Product(s) : Pegloticase,Methotrexate
Therapeutic Area : Rheumatology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegloticase,Methotrexate
Therapeutic Area : Rheumatology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Results show that 71% (71 of 100) of patients who were randomized to receive KRYSTEXXA with methotrexate compared to 40% (21 of 52) of patients who were randomized to receive KRYSTEXXA with placebo achieved the primary endpoint (p<0.001).
Product Name : Krystexxa
Product Type : Enzyme
Upfront Cash : Inapplicable
October 25, 2021
Lead Product(s) : Pegloticase,Methotrexate
Therapeutic Area : Rheumatology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegloticase
Therapeutic Area : Rheumatology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Prospective Study of Pegloticase in Transplant patients trial is an ongoing Phase 4, open-label trial evaluating the safety and efficacy of KRYSTEXXA in adults with uncontrolled gout who have received a kidney transplant and are on stable immunosuppr...
Product Name : Krystexxa
Product Type : Enzyme
Upfront Cash : Inapplicable
June 02, 2021
Lead Product(s) : Pegloticase
Therapeutic Area : Rheumatology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable